Microbio has been featured by Smart Company in an article highlighting the commercialisation of InfectID-BSI and how it has benefitted from our participation in the Brisbane Economic Development Agency’s MedTech Accelerator program. Microbio develops pathogen test to identify and treat sepsis (smartcompany.com.au)
News
Microbio Shareholder Rights to Receive Documents
Microbio Shareholder Notice of Rights to Receive Documents
September is Sepsis Awareness Month
Every September the world marks Sepsis Awareness Month. This year Microbio celebrates the incredible work undertaken by sepsis organisations around the world, who are raising awareness, advocating for survivors and improving sepsis management. Follow us on LinkedIn and X to find out the latest statistics, learn the signs and read the stories of sepsis patients… Continue reading September is Sepsis Awareness Month
Microbio appoints Jeff Bryant to drive global commercial strategy
Microbio Ltd, an Australian pathogen detection diagnostics company, is pleased to announce the appointment of Jeff Bryant as its Commercial Director. Mr Bryant will lead the company’s commercial team as it executes its global commercialisation strategy. With his extensive experience in market entry strategy, sales growth, and sales channel development, Mr Bryant brings valuable expertise… Continue reading Microbio appoints Jeff Bryant to drive global commercial strategy
Microbio presents at ASM Microbe 23
Microbio was honoured to deliver a presentation and two posters at the American Society for Microbiology (ASM) flagship annual meeting, Microbe. ASM Microbe is one of the world’s largest microbial science meetings and was held in Houston, Texas 15-19 June 2023. Abstract presentation Microbio’s Chief Scientific Officer, Dr Flavia Huygens presented in Session ID023: Getting… Continue reading Microbio presents at ASM Microbe 23